HCA Healthcare Reports Q1 Earnings of $7.15, Up 11% Despite Soft Volumes

HCA Healthcare (NYSE: HCA) reported first-quarter 2026 earnings of $7.15 per share, marking an 11% increase from $6.45 in the prior year period, as the hospital operator navigated through an unusually light flu season and weather disruptions.

The Nashville-based company's revenue reached $19.11 billion, up 4.3% from $18.32 billion a year earlier, driven by higher revenue per admission despite minimal volume growth. Net income edged up 0.6% to $1.62 billion.

Key Numbers

HCA's performance reflected mixed operational trends in the quarter. Same-facility admissions grew a modest 0.9%, while equivalent admissions (which include outpatient activity) increased 1.3%. The company compensated for sluggish volume with pricing power, as same-facility revenue per equivalent admission jumped 3.1%.

The volume softness stemmed from two primary factors: respiratory-related admissions plummeted 42% compared to last year's stronger flu season, while respiratory emergency room visits dropped 32%. Additionally, January winter storms disrupted operations in certain markets.

Surgical volumes showed particular weakness, with same-facility inpatient surgeries declining 0.3% and outpatient surgeries falling 1.7%. Emergency room visits barely budged, rising just 0.3%.

Despite operational headwinds, adjusted EBITDA grew 1.9% to $3.80 billion. The company's EBITDA margin compressed to 19.9% from 20.4% a year ago, reflecting higher operating costs. Operating cash flow provided a bright spot, surging 22% to $2.01 billion.

What Management Said

CEO Sam Hazen acknowledged the challenging start to 2026, stating, "The start of the year presented a dynamic environment for HCA Healthcare. I want to recognize our colleagues for continuing to demonstrate a remarkable ability to adapt to changing conditions and deliver for our patients, communities, and stakeholders."

Management noted that the company "did not experience a typical seasonal volume increase" in the first quarter, primarily due to lower respiratory activity. However, they emphasized that unfavorable volume impacts were "mostly offset by the recognition of certain Medicaid supplemental programs that were not included in the Company's initial 2026 guidance."

Notably, HCA reaffirmed its full-year 2026 guidance despite the soft start, suggesting management expects conditions to improve. The guidance assumes "volume growth coupled with an anticipated mostly stable operating environment" and incorporates the company's "resiliency initiatives" to offset potential headwinds.

What to Watch

Several factors merit investor attention going forward. First, the company faces uncertainty around the expiration of enhanced premium tax credits at year-end 2025, which could increase the uninsured patient population and pressure bad debt expense.

HCA's ability to sustain pricing power will be critical, especially if volumes remain subdued. The 3.1% increase in revenue per admission helped offset weak volumes this quarter, but this dynamic may not persist indefinitely.

Capital deployment remains aggressive, with $1.12 billion in capital expenditures during the quarter and $1.57 billion spent repurchasing 3.16 million shares. The company maintains $9.18 billion remaining under its share repurchase authorization and declared a $0.78 quarterly dividend.

Debt levels warrant monitoring, with total debt at $48.02 billion against $940 million in cash. However, the company maintains $4.34 billion of availability under its credit facility, providing financial flexibility.

The normalized respiratory season comparison should become easier in coming quarters, potentially supporting stronger year-over-year volume growth. Additionally, the company's resiliency initiatives and Medicaid supplemental payment recognition could provide earnings support even if the operating environment remains challenging.

For investors, HCA's ability to grow earnings double-digits despite minimal volume growth demonstrates the company's pricing power and operational execution. However, sustained volume weakness could eventually pressure margins and limit the company's ability to offset headwinds through price increases alone.

*StockCliff Research*